Results of IFN-A Therapy in Early Chronic-Phase CML by IFN-A Dose Delivered
| Study (Reference) . | No. of Patients . | Median IFN-A Daily Dose (MU/m2) . | CG Response . | Median Survival (mo) . | ||||
|---|---|---|---|---|---|---|---|---|
| Planned . | Delivered . | CHR . | Any . | Major . | Complete . | |||
| MDACC (2) | 274 | 5 | 5 | 80 | 56 | 38 | 26 | 89 |
| Mahon (14) | 52 | 5 | 5 | 81 | — | 44 | 38 | — |
| ICSG-CML (11) | 218 | 5 | 4.3 | 62 | 55 | 19 | 8 | 72 |
| Alimena (4) | 65 | 1 to 2.5 | — | 46 | 55 | 12 | — | — |
| Ozer (9) | 107 | 5 | 3.2 | 59 | — | 29 | 13 | 66 |
| Allan (12) | 293 | 3 to 12 | 2 (3.2 daily) | 68 | 22 | 11 | 6 | 61 |
| Hehlmann (13) | 133 | 5 | 3 to 4 | 31 | 18 | 10 | 7 | 66 |
| Benelux (1) | 100 | 1.3 (2.14 daily) | 1.3 | 62 | 40 | 7 | 9 | 64 |
| Study (Reference) . | No. of Patients . | Median IFN-A Daily Dose (MU/m2) . | CG Response . | Median Survival (mo) . | ||||
|---|---|---|---|---|---|---|---|---|
| Planned . | Delivered . | CHR . | Any . | Major . | Complete . | |||
| MDACC (2) | 274 | 5 | 5 | 80 | 56 | 38 | 26 | 89 |
| Mahon (14) | 52 | 5 | 5 | 81 | — | 44 | 38 | — |
| ICSG-CML (11) | 218 | 5 | 4.3 | 62 | 55 | 19 | 8 | 72 |
| Alimena (4) | 65 | 1 to 2.5 | — | 46 | 55 | 12 | — | — |
| Ozer (9) | 107 | 5 | 3.2 | 59 | — | 29 | 13 | 66 |
| Allan (12) | 293 | 3 to 12 | 2 (3.2 daily) | 68 | 22 | 11 | 6 | 61 |
| Hehlmann (13) | 133 | 5 | 3 to 4 | 31 | 18 | 10 | 7 | 66 |
| Benelux (1) | 100 | 1.3 (2.14 daily) | 1.3 | 62 | 40 | 7 | 9 | 64 |